ArticleFrontiers in public health2026

Cost-effectiveness analysis of toripalimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma.

Chuangao Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.